In 2026, the primary strategic goal for South America is reducing "Technological Dependency." The creation of the Regional Center for Vaccines and Biotherapeutics (CEVALDBIO) has unified regulatory standards across the Mercosur trade bloc.

By harmonizing clinical trial requirements, a biopharmaceutical product approved in Brazil can now follow an "accelerated pathway" for approval in Argentina and Chile. This has led to a $30\%$ reduction in the time it takes to bring locally produced biologics to market, ensuring that life-saving treatments for conditions like rheumatoid arthritis reach patients faster and at a lower cost to national health budgets.